Versiti launches Beacon Biologics to help deliver custom solutions
Category: #health  By Pankaj Singh  Date: 2021-04-29
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Versiti launches Beacon Biologics to help deliver custom solutions

Versiti, a leader in blood health innovation, has reportedly launched a new platform, Beacon Biologics. This new platform has been introduced with an aim to improve the delivery of custom solutions of well-characterized and high-quality biomaterials to cell therapy developers and researchers.

Beacon Biologics leverages the expertise of Versiti in donor recruitment, apheresis procedures and drug collection, as well as its multi-state blood network. This will help deliver customized LeukoPaks®, blood products, & seamless support to the researchers that focus on advancing the novel treatments for different types of autoimmune disorders, cancers, and other rare diseases. The IRB-approved registry database of the organization includes CMV status, high-resolution HLA typing, and other criteria for donor selection.

Versiti, since its launch, has been supporting the growth of healthcare partners across the nation to ensure the health and safety of the patients. The company offers innovative and value-added solutions in various fields like transplantation, transfusion medicine, and blood-related diseases to cater to the needs of the customers. These strong efforts have resulted in improved patient outcomes, cost efficiencies for the healthcare systems, and expanded access to care nationwide.

As per the statement made by Brad Pietz, Beacon Biologics’ Executive Vice President, and Versiti’s Chief Laboratory Officer & Executive Vice President, the Beacon Biologics platform is positioned to deliver biomaterials fitting select criteria for the longitudinal studies. The platform has leveraged decades of unparalleled expertise and capabilities in blood research as well as developed a dedicated recruitment & collections center to offer comprehensive biomaterial solutions needed for medical advancements to the researchers.

Furthermore, Beacon Biologics was built on Versiti’s 70 years of history in the field of blood product collection and its recognized blood- & transfusion-related research. The company’s renowned BRI (Blood Research Institute) consists of 24 principal investigators who place a high emphasis on the research activities related to blood and blood transfusion.

Source credit:

https://www.prnewswire.com/news-releases/versiti-launches-beacon-biologics-to-provide-custom-solutions-to-researchers-and-cell-therapy-developers-301279197.html



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

MGMA partners with WhiteSpace Health to unveil MGMA DataDiscovery tool

MGMA partners with WhiteSpace Health to unveil MGMA DataDiscovery tool

By Pankaj Singh

Well-known medical practice management organization, Medical Group Management Association (MGMA) has reportedly joined forces with WhiteSpace Health to release a new medical group analytics tool, MGMA DataDiscovery. Th...

Santex acquires U.S. online retailer Parentgiving for market expansion

Santex acquires U.S. online retailer Parentgiving for market expansion

By Pankaj Singh

Italy-based personal care and incontinence product manufacturer Santex SPA has reportedly acquired Parentgiving Inc., America’s top-rated e-commerce retailer of geriatric care products.

LVMH revamps La Samaritaine store and opens it in tourist-less Paris

LVMH revamps La Samaritaine store and opens it in tourist-less Paris

By Pankaj Singh

La Samaritaine, a historic landmark of 19th century France, has been reportedly revamped as a new destination for dining, all-in-one shopping, and tourism by LVMH, a French luxury conglomerate. The stores&rs...